Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology
Atriva Therapeutics and Canadian Biocure Technologies, Inc. entered into an exclusive letter agreement for a reverse takeover transaction.
- Atriva Therapeutics and Canadian Biocure Technologies, Inc. entered into an exclusive letter agreement for a reverse takeover transaction.
- TÜBINGEN, Germany and MUNICH, Germany, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Atriva Therapeutics GmbH (“Atriva”) is pleased to disclose the signing of an exclusive letter agreement, dated September 14, 2023, with Biocure Technology Inc. (“CURE”) (CSE: CURE), based in Vancouver, Canada.
- “We are delighted to have entered into this exclusive letter agreement with Biocure.
- “This letter agreement underscores our commitment to leverage this transaction with CURE as an attractive growth option for Atriva and its stakeholders.